Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Items 101–200 of 1,035
Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695
“Tumor vessels are irregular, disorderly structured, and inefficiently perfused, thereby impairing perfusion and drug delivery (Jain, 2005).”
BackgroundConquering the Hypoxia Limitation for Photodynamic Therapy
Wan, Y., Fu, L., Li, C., Lin, J., & Huang, P. (2021) · Advanced Materials · doi:10.1002/adma.202103978 · Cited by 705
Kudo, M., Kawamura, Y., Hasegawa, K., Tateishi, R., Kariyama, K., Shiina, S., Toyoda, H., Imai, Y., Hiraoka, A., Ikeda, M., et al. (2021) · Liver Cancer · doi:10.1159/000514174 · Cited by 678
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691
“The molecular mechanisms causing these abnormal vascular architectures are not well understood, but the imbalance of pro- and anti-angiogenic factors is considered to be a key contributor (Jain, 2005).”
BackgroundSelf-citationLee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Shrimali, R. K., Yu, Z., Theoret, M. R., Chinnasamy, D., Restifo, N. P., & Rosenberg, S. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0153 · Cited by 677
“Although the inhibition of growth of tumor vessels seems to play a role, there is considerable evidence that normalization of the properties of the tumor vasculature can substantially enhance drug penetration into tumors (22, 23).”
Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Self-citationAnti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
“However, pruning of vessels after antiangiogenic treatments was shown to increase hypoxia, which in turn promoted the rapid tumor progression via multiple mechanisms, including increased migration, inflammation and stem-like cell phenotype [25, 26].”
Arifin, D. Y., Lee, L. Y., & Wang, C.-H. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.007 · Cited by 674
“Jain [152] hypothesized that the antiangiogenic therapy normalized the tumor vascularization so it inhibited the tumor growth and helped the Drug Delivery to the tumor site.”
BackgroundSkeletal muscle: A review of molecular structure and function, in health and disease
Mukund, K., & Subramaniam, S. (2020) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1462 · Cited by 664
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
“sion, hypoxia, acidity, and a high interstitial fluid pressure (5, 6, 9).”
InfluentialSelf-citationImproving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
The Role of Angiogenesis in Cancer Treatment
Rajabi, M., & Mousa, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020034 · Cited by 656
Xu, M., Qi, Y., Liu, G., Song, Y., Jiang, X., & Du, B. (2023) · ACS Nano · doi:10.1021/acsnano.3c05853 · Cited by 632
Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
Thurber, G. M., Schmidt, M. M., & Wittrup, K. D. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.04.012 · Cited by 624
“Improved tumor perfusion and convective flow may also be achieved by vascular ‘normalization’ with anti-angiogenic drugs [149,150].”
BackgroundA role for VEGF as a negative regulator of pericyte function and vessel maturation
Greenberg, J. I., Shields, D. J., Barillas, S. G., Acevedo, L. M., Murphy, E., Huang, J., Scheppke, L., Stockmann, C., Johnson, R. S., Angle, N., et al. (2008) · Nature · doi:10.1038/nature07424 · Cited by 629
Jain, R. K., Tong, R. T., & Munn, L. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4102 · Cited by 612
“‘‘normalize’’ tumor vessels (23, 24) and to reduce IFP in a variety of tumors in mice and in rectal carcinomas in patients (refs.”
BackgroundSelf-citationSynergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608
“Jain established a model to describe the transient status of tumor vessel undergoing anti-angiogenesis: vessel normalization [53].”
BackgroundMethodInfluentialAnti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A. A., Fack, F., Thorsen, F., Taxt, T., Bartos, M., Jirik, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014480108 · Cited by 606
“flow and oxygenation (normalization hypothesis) (1, 21, 36).”
BackgroundDelivery of Molecular and Nanoscale Medicine to Tumors: Transport Barriers and Strategies
Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114300 · Cited by 597
Self-citationTumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
Fukumura, D., & Jain, R. K. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21187 · Cited by 584
“Some direct and indirect anti-angiogenic therapies might ‘‘normalize’’ the tumor vasculature through this mechanism [Jain, 2005].”
BackgroundMethodInfluentialSelf-citationThe biology of brain metastases—translation to new therapies
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.58 · Cited by 567
Self-citationTumour vascularization: sprouting angiogenesis and beyond
Hillen, F., & Griffioen, A. W. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9094-7 · Cited by 583
“The successful combination of chemotherapy and anti-angiogenesis therapy may benefit from the normalization of the tumour vasculature by anti-angiogenic therapy and subsequently a better administration of chemotherapy [165].”
BackgroundTherapeutic targeting of the tumor microenvironment
Joyce, J. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.024 · Cited by 582
“Strategies to overcome these environmental barriers, by reducing IFP or “normalizing” the vasculature for example, have been championed by Jain, Heldin, and others (Heldin et al., 2004; Jain, 2001; Jain, 2005).”
Butler, J. M., Kobayashi, H., & Rafii, S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2791 · Cited by 578
Biomarkers of response and resistance to antiangiogenic therapy
Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572
Self-citationStylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Self-citationFLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Fischer, C., Mazzone, M., Jonckx, B., & Carmeliet, P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2524 · Cited by 568
“Additional mechanisms might relate to the fact that αPlGF promotes vessel normalization (which would be expected to improve drug deliver”
BackgroundEmerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
“which could potentially enhance the efficacy of radiation and chemotherapy by alleviating hypoxia and tumor invasiveness”
BackgroundSelf-citationVascular normalization in Rgs5-deficient tumours promotes immune destruction
Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H.-J., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 564
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Shields, J. D., Fleury, M. E., Yong, C., Tomei, A. A., Randolph, G. J., & Swartz, M. A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.020 · Cited by 552
“Furthermore, it is well established that tumors are highly vascularized and contain abnormally leaky capillaries (Jain, 2003, 2005; Carmeliet, 2003); tumor fluid flows through the interstitial space toward the draining lymphatics with a velocity of 0.1–0.8 mm/s (Chary and Jain, 1989; Dafni et al.,…”
BackgroundInfluentialHyperthermia adds to chemotherapy
Issels, R. D. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.07.038 · Cited by 545
Li, H.-J., Du, J.-Z., Liu, J., Du, X.-J., Shen, S., Zhu, Y.-H., Wang, X., Ye, X., Nie, S., & Wang, J. (2016) · ACS Nano · doi:10.1021/acsnano.6b02326 · Cited by 537
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Plotkin, S. R., Stemmer-Rachamimov, A. O., Barker, F. G., Halpin, C., Padera, T. P., Tyrrell, A., Sorensen, A. G., Jain, R. K., & di Tomaso, E. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902579 · Cited by 532
Self-citationNormalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
“Here, we describe how cancer cells coopt endothelial, perivascular, fibroblast, and immune cells to collaborate toward producing abnormal vessels, which produce a hypoxic and acidic microenvironment that fuels vessel abnormality, thereby creating a vicious cycle (3, 54).”
BackgroundSelf-citationAdipocyte and lipid metabolism in cancer drug resistance
Cao, Y. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127201 · Cited by 522
“Even though the tumor tissue is hypervascularized, the disorganized, tortuous, and leaky tumor vasculature is poorly perfused, and drug perfusion is limited (129, 130).”
BackgroundThe Contribution of Angiogenesis to the Process of Metastasis
Bielenberg, D. R., & Zetter, B. R. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000138 · Cited by 523
Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520
Self-citationTian, S., Quan, H., Xie, C., Guo, H., Lü, F., Xu, Y., Li, J., & Lou, L. (2011) · Cancer Science · doi:10.1111/j.1349-7006.2011.01939.x · Cited by 513
Hypoxia and Radiation Therapy: Past History, Ongoing Research, and Future Promise
Rockwell, S., Dobrucki, I., Kim, E., Marrison, S., & Vu, V. (2009) · Current Molecular Medicine · doi:10.2174/156652409788167087 · Cited by 511
Combining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
de Groot, J. F., Fuller, G., Kumar, A. J., Piao, Y., Eterovic, K., Ji, Y., & Conrad, C. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop027 · Cited by 509
“It has been suggested that antiangiogenic therapy leads to vascular normalization, with the expected consequence of improving oxygen delivery and potentially increasing drug delivery to tumor.(14,27) These changes are expected to occur within a transient “window” of time.”
BackgroundWillett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
“The local control and survival data suggest that normalization of the tumor vasculature by bevacizumab may have important and positive clinical consequences.(12,13) Finally, the potential biomarker candidates emerging from this study should be further evaluated in larger studies to validate them, with the goal of opti…”
BackgroundSelf-citationThe Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Gotink, K. J., & Verheul, H. M. W. (2010) · Angiogenesis · doi:10.1007/s10456-009-9160-6 · Cited by 501
“In addition, it is suggested that chemotherapy and radiation therapy may also directly damage endothelial cells, and thus may enhance antiangiogenic effects [21, 97].”
BackgroundTargeting antioxidants for cancer therapy
Glasauer, A., & Chandel, N. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.017 · Cited by 499
“As mentioned previously, hypoxia is a hallmark characteristic of many cancers [58] and has been shown to increase ROS production [59].”
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
“The process of vascular normalization (discussed below) [22], which stabilizes new vessels [23], is also assumed to result in increased oxygenation leading to enhanced sensitivity to radiotherapy and chemotherapy [24].”
Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
Primeau, A. J., Rendon, A., Hedley, D., Lilge, L., & Tannock, I. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1664 · Cited by 499
Fluid forces control endothelial sprouting
Song, J. W., & Munn, L. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105316108 · Cited by 498
“Implicit in these processes are endothelial proliferation during expansion of the vasculature and their loss during vessel contraction and pruning (7).”
BackgroundDromi, S., Frenkel, V., Luk, A., Traughber, B., Angstadt, M., Bur, M., Poff, J., Xie, J., Libutti, S. K., Li, K. C. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2443 · Cited by 492
“Abnormal and heterogeneous distribution of inefficient vasculature (2), high interstitial fluid pressures (3), and fibrillar collagen in the extracellular matrix (4) are some of the barriers that further complicate effective and”
BackgroundAntibody–drug conjugates as novel anti-cancer chemotherapeutics
Peters, C., & Brown, S. (2015) · Bioscience Reports · doi:10.1042/bsr20150089 · Cited by 492
“ADCs that bind to neovasculature destroy the tumour blood supply and cause tumour cell death via nutrient deprivation and hypoxia [75] [76].”
BackgroundMolecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1366 · Cited by 481
Self-citationPaciotti, G. F., Kingston, D. G. I., & Tamarkin, L. (2006) · Drug Development Research · doi:10.1002/ddr.20066 · Cited by 484
Stylianopoulos, T., Martin, J. D., Snuderl, M., Mpekris, F., Jain, S. R., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4521 · Cited by 477
“An understanding of causes and adverse consequences of the interstitial hypertension in tumor progression and treatment has led to clinically translatable strategies to lower tumor IFP in animal models and cancer patients (29, 30).”
Self-citationCheng, G., Tse, J., Jain, R. K., & Munn, L. L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004632 · Cited by 478
“rameters, such as hypoxia [1,2] and angiogenesis [3–5], mechanical”
BackgroundSelf-citationVEGF and angiopoietin signaling in tumor angiogenesis and metastasis
Saharinen, P., Eklund, L., Pulkki, K., Bono, P., & Alitalo, K. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.01.015 · Cited by 478
Ultrasound mediated delivery of drugs and genes to solid tumors
Frenkel, V. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.03.007 · Cited by 474
“The vasculature is also chaotic in regards to spatial distribution, microvessel length and diameter [6], and it can be tortuous and saccular, possessing haphazard interconnections, which renders the vessels functionally abnormal [9].”
BackgroundZhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 477
Self-citationGoveia, J., Rohlenova, K., Taverna, F., Treps, L., Conradi, L.-C., Pircher, A., Geldhof, V., de Rooij, L. P. M. H., Kalucka, J., Sokol, L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.001 · Cited by 468
“AAT is considered to prune angiogenic ECs, although VEGF blockade can also normalize the abnormal tumor vasculature (‘‘tumor vessel normalization’’) (Jain, 2005).”
BackgroundAntiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer?
Kerbel, R. S. (2006) · Science · doi:10.1126/science.1125950 · Cited by 466
Broad targeting of angiogenesis for cancer prevention and therapy
Wang, Z., Dabrosin, C., Yin, X., Fuster, M. M., Arreola, A., Rathmell, W. K., Generali, D., Nagaraju, G. P., El-Rayes, B., Ribatti, D., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.01.001 · Cited by 464
“nd perfusion in the tumor and thus reduce the pathological charcteristics of the vessels, for example via sub-maximal dosing of nti-angiogenic drugs [19].”
BackgroundStrategies for optimizing the response of cancer and normal tissues to radiation
Moding, E. J., Kastan, M. B., & Kirsch, D. G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4003 · Cited by 461
miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial Cells
Würdinger, T., Tannous, B. A., Saydam, O., Skog, J., Grau, S., Soutschek, J., Weissleder, R., Breakefield, X. O., & Krichevsky, A. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.005 · Cited by 463
“The state of angiogenesis is a balance between pro- and antiangiogenic molecules, with a bias toward the proangiogenic mode (Jain, 2005).”
BackgroundPeng, Z., Fan, W., Zhu, B., Wang, G., Sun, J., Xiao, C., Huang, F., Tang, R., Cheng, Y., Huang, Z., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.00392 · Cited by 460
“Second, LEN promotes tumor vascular normalization, which would be expected to enhance response rates by improving embolism agent delivery and optimizing the embolization effect,(24) as well as optimizing delivery of systemic anticancer drugs within the tumor through reduction of tumor vascular permeability and interst…”
BackgroundChang, Y. S., Adnane, J., Trail, P. A., Levy, J., Henderson, A., Xue, D., Bortolon, E., Ichetovkin, M., Chen, C., McNabola, A., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0393-4 · Cited by 459
“It has been proposed that one of the mechanisms by which anti-vascular agents mediate their eVect is to transiently “normalize” tumor vasculature, resulting in enhanced delivery of oxygen, nutrients, and chemotherapeutic agents [22].”
BackgroundPietras, K., Pahler, J., Bergers, G., & Hanahan, D. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050019 · Cited by 453
“, dasatinib) might prove beneficial when combined with VEGF receptor inhibitors and/or with chemotherapy in more flexible combinations than strictly simultaneous dosing, involving evolutions of the chemo-switch regimen [36]; thus we might imagine first normalizing the tumor vasculature with VEGF pathway inhibitors [65…”
BackgroundSung, Y.-C., Jin, P.-R., Chu, L.-A., Hsu, F.-F., Wang, M.-R., Chang, C.-C., Chiou, S.-J., Qiu, J. T., Gao, D.-Y., Lin, C.-C., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0570-3 · Cited by 452
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 453
FUKUMURA, D., DUDA, D. G., MUNN, L. L., & JAIN, R. K. (2010) · Microcirculation · doi:10.1111/j.1549-8719.2010.00029.x · Cited by 451
“IVM has provided unique insights into angiogenesis and tumor biology [12,34,36,71,86].”
BackgroundSelf-citationVascular Endothelial Growth Factor as an Anti-Angiogenic Target for Cancer Therapy
Niu, G., & Chen, X. (2010) · Current Drug Targets · doi:10.2174/138945010791591395 · Cited by 451
Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers
Zhao, Z., Ukidve, A., Krishnan, V., & Mitragotri, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.002 · Cited by 444
MicroRNAs: Novel regulators in the hallmarks of human cancer
Ruan, K., Fang, X., & Ouyang, G. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.04.031 · Cited by 447
“The state of angiogenesis is a balance between pro- and anti-angiogenic factors, with a bias towards the pro-angiogenic mode [65].”
BackgroundNon–Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT
Ganeshan, B., Goh, V., Mandeville, H. C., Ng, Q. S., Hoskin, P. J., & Miles, K. A. (2013) · Radiology · doi:10.1148/radiol.12112428 · Cited by 447
Tumor and its microenvironment: A synergistic interplay
Catalano, V., Turdo, A., Di Franco, S., Dieli, F., Todaro, M., & Stassi, G. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.08.007 · Cited by 444
“[105] Jain RK.”
BackgroundThe concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 443
“Antiangiogenic and anti-VEGF therapy in combination with radiation Angiogenesis is essential for sustained tumor growth, and many new cancer therapies are directed against modification of the tumor vasculature”
BackgroundGeiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
Adipose tissue angiogenesis as a therapeutic target for obesity and metabolic diseases
Cao, Y. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3055 · Cited by 442
Dissecting cancer through mathematics: From the cell to the animal model
Byrne, H. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2808 · Cited by 442
“The models also support the emerging concept that treatment with anti-angiogenic compounds can transiently normalize the structure and function of the tumour vasculature and therefore reduce the degree of tumour hypoxia and enhance the response to chemotherap”
ResultDickson, P. V., Hamner, J. B., Sims, T. L., Fraga, C. H., Ng, C. Y. C., Rajasekeran, S., Hagedorn, N. L., McCarville, M. B., Stewart, C. F., & Davidoff, A. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0278 · Cited by 441
The role of pericytes in angiogenesis
Ribatti, D., Nico, B., & Crivellato, E. (2011) · The International Journal of Developmental Biology · doi:10.1387/ijdb.103167dr · Cited by 440
“and JAIN, R.K. (1998). Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment.”
BackgroundThe tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives
Sun, R., Xiang, J., Zhou, Q., Piao, Y., Tang, J., Shao, S., Zhou, Z., Bae, Y. H., & Shen, Y. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114614 · Cited by 433
Shaked, Y., Henke, E., Roodhart, J. M. L., Mancuso, P., Langenberg, M. H. G., Colleoni, M., Daenen, L. G., Man, S., Xu, P., Emmenegger, U., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.001 · Cited by 440
“…of standard chemotherapy using drugs such as bevacizumab, relative to other proposed mechanisms such as transiently induced vessel normalization (Jain, 2005; Winkler et al., 2004), or enhancement of the extent of local damage to the tumor vasculature mediated by chemotherapy, in the clinical…”
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin
Phung, T. L., Ziv, K., Dabydeen, D., Eyiah-Mensah, G., Riveros, M., Perruzzi, C., Sun, J., Monahan-Earley, R. A., Shiojima, I., Nagy, J. A., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.07.003 · Cited by 438
“Thus, the desire for vascular normalization has become an important consideration in antiangiogenic therapy (Jain, 2005).”
BackgroundSelf‐Healing Materials with Interpenetrating Microvascular Networks
Hansen, C. J., Wu, W., Toohey, K. S., Sottos, N. R., White, S. R., & Lewis, J. A. (2009) · Advanced Materials · doi:10.1002/adma.200900588 · Cited by 434
Li, C., Zhang, Y., Wang, M., Zhang, Y., Chen, G., Li, L., Wu, D., & Wang, Q. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.010 · Cited by 428
“The growth of new blood vessels from pre-existing vasculature, namely, angiogenesis, is essential for tumor growth and metastasis and is a promising target for cancer therapy [35,36].”
BackgroundThe acidic tumor microenvironment: a target for smart cancer nano-theranostics
Feng, L., Dong, Z., Tao, D., Zhang, Y., & Liu, Z. (2018) · National Science Review · doi:10.1093/nsr/nwx062 · Cited by 426
Deryugina, E. I., & Quigley, J. P. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.04.004 · Cited by 422
“…flow are among the “normalization” responses of tumor-associated vasculature to antiangiogenic therapies (Carmeliet and Jain, 2011; Goel et al., 2011; Jain, 2005), which can lead to accelerated tumor progression and enhanced distant metastasis (Ebos et al., 2009; Loges et al., 2009; Paez-Ribes et…”
BackgroundAndrogen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 420
“Although the mechanism of action has not been elucidated, adding ADT may enhance radiation effects via increased tumor oxygenation (Zietman et al., 1997a; Zietman et al., 1997b; Kaminski et al., 2003; Jain, 2005; Stewart et al., 2011) and also by preventing dissemination of micro-metastatic disease.”
BackgroundHeterogeneity of the Tumor Vasculature
Nagy, J., Chang, S.-H., Shih, S.-C., Dvorak, A., & Dvorak, H. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1253454 · Cited by 422
Endothelial sprouting and angiogenesis: matrix metalloproteinases in the lead
van Hinsbergh, V. W. M., & Koolwijk, P. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvm102 · Cited by 420
“In a number of pathological conditions, in particular in tumours, massive angiogenic sprouting occurs, but the process remains stuck in the expansion phase resulting in a disorganized and poorly perfused neovasculature.(3) The process of angiogenesis is accompanied by the recruitment of circulating cells, which contri…”
BackgroundEngineered nanomedicines with enhanced tumor penetration
Ding, J., Chen, J., Gao, L., Jiang, Z., Zhang, Y., Li, M., Xiao, Q., Lee, S. S., & Chen, X. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100800 · Cited by 420
Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420
Self-citationMatrix stiffening promotes a tumor vasculature phenotype
Bordeleau, F., Mason, B. N., Lollis, E. M., Mazzola, M., Zanotelli, M. R., Somasegar, S., Califano, J. P., Montague, C., LaValley, D. J., Huynh, J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613855114 · Cited by 416
“Notably, tumor angiogenesis is marked by increased branching and tortuosity (5).”
BackgroundDudley, A. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006536 · Cited by 424
Trafficking of T Cells into Tumors
Slaney, C. Y., Kershaw, M. H., & Darcy, P. K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2458 · Cited by 410
Precise nanomedicine for intelligent therapy of cancer
Chen, H., Gu, Z., An, H., Chen, C., Chen, J., Cui, R., Chen, S., Chen, W., Chen, X., Chen, X., et al. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9397-5 · Cited by 409
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.